Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
BMC Cancer
    October 2025
  1. CHEN B, Zhou Y, Li Z, Chen J, et al
    A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics.
    BMC Cancer. 2025;25:1497.
    >> Share

    September 2025
  2. LIU S, Lei K, Li G, Zheng P, et al
    The integration of transcriptomics and metabolomics elucidates the antitumor mechanisms of mycophenolic acid in bladder cancer cells.
    BMC Cancer. 2025;25:1463.
    >> Share

  3. LI C, Liu J, Wang L, Xiong W, et al
    Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer immunotherapy by inhibiting CD276 expression.
    BMC Cancer. 2025;25:1404.
    >> Share

    July 2025
  4. LI J, Liang J, Xu Y, Tan W, et al
    Droplet digital PCR assay for precise determination of FRS2 gene copy number in bladder cancer.
    BMC Cancer. 2025;25:1211.
    >> Share

  5. WANG B, Gong Z, Su P, Zhen G, et al
    Multi-machine learning model based on radiomics features to predict prognosis of muscle-invasive bladder cancer.
    BMC Cancer. 2025;25:1116.
    >> Share

  6. HUANG L, Yan D, Ruan H, Lin Q, et al
    BAIAP2 as a driver of tumor progression in urothelial bladder cancer.
    BMC Cancer. 2025;25:1057.
    >> Share

    June 2025
  7. PAN Y, Shih HJ, Chuang SH, Chang CP, et al
    Effects of functional antioxidants on the expansion of gamma delta T-cells and their cellular cytotoxicity against bladder cancer cells.
    BMC Cancer. 2025;25:980.
    >> Share

    May 2025
  8. XU M, Zhou J, Lv J, Zhang Y, et al
    Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis.
    BMC Cancer. 2025;25:932.
    >> Share

  9. N S, Ps H, P R, Paul L, et al
    Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer.
    BMC Cancer. 2025;25:916.
    >> Share

  10. LAN T, Zhu Y, Zhong W, Tan Q, et al
    Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial.
    BMC Cancer. 2025;25:868.
    >> Share

    April 2025
  11. WANG X, Qu Y, Sun Y, Yang T, et al
    ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling.
    BMC Cancer. 2025;25:789.
    >> Share

  12. KITAHAMA K, Shigematsu Y, Sugawara E, Amori M, et al
    Clinicopathological characteristics of transcription factor-defined subtypes in bladder small cell carcinoma.
    BMC Cancer. 2025;25:766.
    >> Share

  13. QIU H, Deng X, Zha J, Wu L, et al
    Machine learning-based characterization of stemness features and construction of a stemness subtype classifier for bladder cancer.
    BMC Cancer. 2025;25:717.
    >> Share

  14. LI Z, Su M, Li Q, Zheng X, et al
    The role of CDK8 gene polymorphisms in bladder cancer susceptibility and prognosis: a study in the Chinese Han population.
    BMC Cancer. 2025;25:714.
    >> Share

  15. PLAGE H, Ahlburg V, Hofbauer S, Furlano K, et al
    Loss of chromosome Y is unrelated to the composition of the tumor microenvironment and patient prognosis in muscle-invasive urothelial bladder cancers.
    BMC Cancer. 2025;25:677.
    >> Share

    March 2025
  16. YANG H, Zhang T, Li Z, Cai Y, et al
    Risk factors for in-hospital venous thromboembolism in patients with bladder cancer: A retrospective single-center study.
    BMC Cancer. 2025;25:536.
    >> Share

  17. WAN S, Li KP, Chen SY, Wang CY, et al
    Single-cell sequencing combined with urinary multi-omics analysis reveals that the non-invasive biomarker PRDX5 regulates bladder cancer progression through ferroptosis signaling.
    BMC Cancer. 2025;25:533.
    >> Share

  18. DAI L, Ye K, Yao G, Lin J, et al
    Using machine learning for predicting cancer-specific mortality in bladder cancer patients undergoing radical cystectomy: a SEER-based study.
    BMC Cancer. 2025;25:523.
    >> Share

  19. SHENG Z, Xu J, Wang M, Xu X, et al
    The role of urinary microbiota in primary and recurrent bladder cancer: insights from a propensity score matching study.
    BMC Cancer. 2025;25:468.
    >> Share

    February 2025
  20. CAI J, Yan Z, Zhong Y, Li Y, et al
    Small non-coding RNA profiling in patients with non-muscle invasive bladder cancer.
    BMC Cancer. 2025;25:319.
    >> Share

  21. ZHENG Z, Dai F, Liu J, Zhang Y, et al
    Pathology-based deep learning features for predicting basal and luminal subtypes in bladder cancer.
    BMC Cancer. 2025;25:310.
    >> Share

  22. YAN L, Liang H, Qi T, Deng D, et al
    Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
    BMC Cancer. 2025;25:297.
    >> Share

  23. WANG C, Li K, Huang R, Wan S, et al
    Urine proteomics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer.
    BMC Cancer. 2025;25:271.
    >> Share

  24. LI Z, Wang Z, Wu J, Zhang F, et al
    Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients.
    BMC Cancer. 2025;25:268.
    >> Share

  25. LI KP, Wan S, Wang CY, Chen SY, et al
    Multi-omics analysis reveals the impact of YAP/TEAD4-mediated EIF5A1 expression on mitochondrial apoptosis and bladder cancer progression.
    BMC Cancer. 2025;25:234.
    >> Share

  26. LI P, Jing S, Kang Y, Feng B, et al
    Clinical outcomes of nephroureterectomy with bladder cuff excision or radical cystectomy for distal ureteral carcinoma invaded muscle of the ureteral orifice.
    BMC Cancer. 2025;25:221.
    >> Share

  27. FURUKAWA J, Kakei Y, Murakami S, Kita H, et al
    Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial.
    BMC Cancer. 2025;25:195.
    >> Share

    January 2025
  28. CHEN T, Zou X, Li Y, Peng L, et al
    Evaluation of the association between lymph node ratio and long-term survival in patients after surgery for lymph node-positive bladder cancer: a SEER population-based study with external validation.
    BMC Cancer. 2025;25:135.
    >> Share

    November 2024
  29. SCHUCK S, Loussikian P, Mebarki A, Malaab J, et al
    Perceived unmet needs and impact on quality of life of patients living with advanced bladder cancer and their caregivers: results of a social media listening study conducted in five European countries.
    BMC Cancer. 2024;24:1444.
    >> Share

    October 2024
  30. FUKUMOTO W, Okamura S, Tamai M, Arima J, et al
    Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.
    BMC Cancer. 2024;24:1333.
    >> Share

  31. KARLSSON P, Nygren-Bonnier M, Torikka S, Porserud A, et al
    Patients experiences of an exercise intervention in primary care following robot-assisted radical cystectomy due to bladder cancer: a qualitative study.
    BMC Cancer. 2024;24:1306.
    >> Share

  32. SONG J, Sun X, Wang T, Li C, et al
    Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.
    BMC Cancer. 2024;24:1261.
    >> Share

  33. YAO Z, Li Y, Ding Y, Hou Y, et al
    Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters >/=3cm compared to transurethral resection: a non-randomized controlled study.
    BMC Cancer. 2024;24:1239.
    >> Share

    September 2024
  34. PALACKA P, Holickova A, Roska J, Makovicky P, et al
    Prognostic value of nucleotide excision repair and translesion DNA synthesis proteins in muscle-infiltrating bladder carcinoma.
    BMC Cancer. 2024;24:1103.
    >> Share

    August 2024
  35. FAN Z, Liu Y, Wang X, Xu Y, et al
    APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis.
    BMC Cancer. 2024;24:1046.
    >> Share

  36. CHEN D, Cao H, Zheng X, Wang H, et al
    Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target.
    BMC Cancer. 2024;24:1024.
    >> Share

  37. BOTROUS S, Elmaghraby A, Achy SE, Mustafa Y, et al
    Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A.
    BMC Cancer. 2024;24:971.
    >> Share

  38. HAO S, Yang Z, Wang G, Cai G, et al
    Development of prognostic model incorporating a ferroptosis/cuproptosis-related signature and mutational landscape analysis in muscle-invasive bladder cancer.
    BMC Cancer. 2024;24:958.
    >> Share

  39. LIU R, Yang T, Huang J, Xiao Z, et al
    Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    BMC Cancer. 2024;24:947.
    >> Share

    July 2024
  40. CICIN I, Plimack ER, Gurney H, Leibowitz R, et al
    Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.
    BMC Cancer. 2024;23.
    >> Share

  41. PORSERUD A, Karlsson P, Aly M, Rydwik E, et al
    Effects of an exercise intervention in primary care after robot-assisted radical cystectomy for urinary bladder cancer: a randomised controlled trial.
    BMC Cancer. 2024;24:891.
    >> Share

  42. IQBAL MS, Sardar N, Peng K, Almutairi LA, et al
    Association between CYP1A2 gene variants -163 C/A (rs762551) and -3860 G/A (rs2069514) and bladder cancer susceptibility.
    BMC Cancer. 2024;24:880.
    >> Share

  43. MOHAMED AH, Mohamed KA, Kayacan E, Nur Y, et al
    Clinical characteristics and factors associated with survival rate of patients with non-muscle invasive bladder cancer attending at a Tertiary Hospital in Somalia.
    BMC Cancer. 2024;24:839.
    >> Share

    June 2024
  44. ZHANG X, Hong B, Li H, Zhao J, et al
    Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer.
    BMC Cancer. 2024;24:746.
    >> Share

  45. MENG H, Yang R, Lin Q, Du W, et al
    Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b.
    BMC Cancer. 2024;24:737.
    >> Share

  46. JI J, Zhang T, Zhu L, Yao Y, et al
    Using machine learning to develop preoperative model for lymph node metastasis in patients with bladder urothelial carcinoma.
    BMC Cancer. 2024;24:725.
    >> Share

    March 2024
  47. LI X, Liang Z, Pan J, Zhang M, et al
    Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer.
    BMC Cancer. 2024;24:328.
    >> Share

    February 2024
  48. HUANG LH, Chen CS, Li JR, Chiu KY, et al
    The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.
    BMC Cancer. 2024;24:247.
    >> Share

  49. ZHANG J, Yang M, Wei D, Zhang D, et al
    The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
    BMC Cancer. 2024;24:202.
    >> Share

  50. YANG M, Zhang J, Wei D, Yu T, et al
    Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
    BMC Cancer. 2024;24:196.
    >> Share

    January 2024
  51. PAN DL, Zhang LF, Li XJ, Zhang KP, et al
    Feasibility and safety of laparoscopic radical cystectomy for male octogenarians with muscle-invasive bladder cancer.
    BMC Cancer. 2024;24:159.
    >> Share

  52. VERGHOTE F, Van Praet C, Berquin C, Lumen N, et al
    Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice.
    BMC Cancer. 2024;24:160.
    >> Share

  53. JING S, Yang E, Luo Z, Zhang Y, et al
    Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer.
    BMC Cancer. 2024;24:127.
    >> Share

    November 2023
  54. GORE JL, Wolff EM, Comstock BA, Follmer KM, et al
    Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    BMC Cancer. 2023;23:1127.
    >> Share

  55. ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
    BMC Cancer. 2023;23:1080.
    >> Share

  56. LU L, Chen C, Cheng H, Ding H, et al
    Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1066.
    >> Share

    October 2023
  57. CHEN JX, Huang WT, Zhang QY, Deng CE, et al
    The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:1018.
    >> Share

  58. LI Y, Xu K, Zhang Y, Mao H, et al
    Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    BMC Cancer. 2023;23:1021.
    >> Share

  59. LUO L, Xie Q, Wu Y, Li P, et al
    Circular RNA CCT3 is a unique molecular marker in bladder cancer.
    BMC Cancer. 2023;23:977.
    >> Share

  60. HE Q, Wu S, Zhou Y, Liu Y, et al
    Genetic factors, adherence to healthy lifestyle behaviors, and risk of bladder cancer.
    BMC Cancer. 2023;23:965.
    >> Share

  61. ZHENHAI Z, Qi C, Shuchao Z, Zhongqi W, et al
    MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.
    BMC Cancer. 2023;23:956.
    >> Share

  62. TANABE K, Nakanishi Y, Okubo N, Matsumoto S, et al
    Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II.
    BMC Cancer. 2023;23:940.
    >> Share

  63. WANG Y, Pan J, An F, Chen K, et al
    GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
    BMC Cancer. 2023;23:925.
    >> Share

    September 2023
  64. ALT M, Stecca C, Lin Y, Kazeem G, et al
    Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
    BMC Cancer. 2023;23:919.
    >> Share

  65. TSAI TH, Su PJ, Huang SY, Kuo MC, et al
    The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
    BMC Cancer. 2023;23:871.
    >> Share

  66. NASR S, Haddad FG, Khazen J, Kattan J, et al
    PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience.
    BMC Cancer. 2023;23:817.
    >> Share

    August 2023
  67. CAI Y, Cheng Y, Wang Z, Li L, et al
    A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    BMC Cancer. 2023;23:725.
    >> Share

  68. JIANG Y, Zhu C, Huang H, Huang G, et al
    TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
    BMC Cancer. 2023;23:716.
    >> Share

    July 2023
  69. LI W, Liu Z, Jin K, Shao F, et al
    Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:661.
    >> Share

    June 2023
  70. KERZELI IK, Kostakis A, Turker P, Malmstrom PU, et al
    Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
    BMC Cancer. 2023;23:605.
    >> Share

  71. LIANG PI, Lai HY, Chan TC, Li WM, et al
    Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
    BMC Cancer. 2023;23:599.
    >> Share

  72. LIU J, Wu P, Lai S, Wang J, et al
    Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning.
    BMC Cancer. 2023;23:574.
    >> Share

  73. NISHIYAMA H, Tanaka Y, Hamada M, Ozaki M, et al
    Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
    BMC Cancer. 2023;23:565.
    >> Share

  74. RUTTEN VC, Salhi Y, Robbrecht GJ, de Wit R, et al
    The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.
    BMC Cancer. 2023;23:539.
    >> Share

  75. KOLL FJ, Doring C, Olah C, Szarvas T, et al
    Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
    BMC Cancer. 2023;23:504.
    >> Share

    April 2023
  76. HUI P, Ni F, Zheng L, Jia L, et al
    Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
    BMC Cancer. 2023;23:355.
    >> Share

  77. TANG Y, Lei Y, Gao P, Jia J, et al
    Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker.
    BMC Cancer. 2023;23:328.
    >> Share

  78. YANG X, Zhang S, Cui Y, Li Y, et al
    Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial.
    BMC Cancer. 2023;23:320.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016